All Studies Meta Analysis Recent:

Ivermectin: an award-winning drug with expected antiviral activity against COVID-19

Formiga et al., J. Control Release, doi:10.1016/j.jconrel.2020.10.009

Jan 2021

Post
Facebook

Source PDF All Studies Meta AnalysisMeta

Ivermectin for COVID-19

4th treatment shown to reduce risk in August 2020

^*, now known with p < 0.00000000001 from 102 studies, recognized in 22 countries.

Lower risk for mortality, ventilation, ICU admission, hospitalization, recovery, cases, and viral clearance.

No treatment is 100% effective. Protocols combine complementary and synergistic treatments. ^* >10% efficacy in meta analysis with ≥3 clinical studies.

4,000+ studies for 60+ treatments. c19ivm.org

Review hypothesizing that micro- and nanotechnology-based formulations of ivermectin for the pulmonary delivery of ivermectin may be beneficial for use with COVID-19.

Reviews covering ivermectin for COVID-19 include Adegboro, Al-kuraishy, Babalola, Behl, Bray, DiNicolantonio, DiNicolantonio (B), Elkholy, Fordham, Formiga, Heidary, Jagiasi, Jans, Jans (B), Kory, Kory (B), Kory (C), Kory (D), Kow, Lind, Liu, Loo, Low, Santin, Scheim, Schwartz, Semiz, Turkia, Turkia (B), Turkia (C), Vora, Wang, Wehbe, Yagisawa, Yagisawa (B), Yemeke, Zaidi.

Important missing comments or errors? Let us know.

1. Adegboro et al., A review of the anti-viral effects of ivermectin, African Journal of Clinical and Experimental Microbiology, doi:10.4314/ajcem.v22i3.2.ajol.info, doi.org.

2. Al-kuraishy et al., Central effects of Ivermectin in alleviation of Covid-19-induced dysautonomia, Current Drug Targets, doi:10.2174/1389450123666220810102406.eurekaselect.com, doi.org.

3. Babalola et al., The Place of Ivermectin in the Management of Covid-19: State of the Evidence, Medical Research Archives, doi:10.18103/mra.v11i4.3778.esmed.org, doi.org.

4. Behl et al., CD147-spike protein interaction in COVID-19: Get the ball rolling with a novel receptor and therapeutic target, Science of The Total Environment, doi:10.1016/j.scitotenv.2021.152072.sciencedirect.com, doi.org.

5. Bray et al., Ivermectin and COVID-19: A report in Antiviral Research, widespread interest, an FDA warning, two letters to the editor and the authors' responses, Antiviral Res., doi:10.1016/j.antiviral.2020.104805.nih.gov, doi.org.

6. DiNicolantonio et al., Anti-inflammatory activity of ivermectin in late-stage COVID-19 may reflect activation of systemic glycine receptors, Open Heart, doi:10.1136/openhrt-2021-001655.bmj.com, doi.org.

7. DiNicolantonio (B) et al., Ivermectin may be a clinically useful anti-inflammatory agent for late-stage COVID-19, Open Heart, doi:10.1136/openhrt-2020-001350.bmj.com, doi.org.

8. Elkholy et al., Ivermectin: A Closer Look at a Potential Remedy, Cureus, doi:10.7759/cureus.10378.cureus.com, doi.org.

9. Fordham et al., The uses and abuses of systematic reviews, OSF Preprints, doi:10.31219/osf.io/mp4f2.osf.io, doi.org.

10. Formiga et al., Ivermectin: an award-winning drug with expected antiviral activity against COVID-19, J. Control Release, doi:10.1016/j.jconrel.2020.10.009.nih.gov, doi.org.

11. Heidary et al., Ivermectin: a systematic review from antiviral effects to COVID-19 complementary regimen, The Journal of Antibiotics, 73, 593–602, doi:10.1038/s41429-020-0336-z.nature.com, doi.org.

12. Jagiasi et al., Variation in therapeutic strategies for the management of severe COVID-19 in India- A nationwide cross-sectional survey, The International Journal of Clinical Practice, doi:10.1111/ijcp.14574.wiley.com, doi.org.

13. Jans et al., The broad spectrum host-directed agent ivermectin as an antiviral for SARS-CoV-2 ?, Biochemical and Biophysical Research Communications, doi:10.1016/j.bbrc.2020.10.042.sciencedirect.com, doi.org.

14. Jans (B) et al., Ivermectin as a Broad-Spectrum Host-Directed Antiviral: The Real Deal?, Cells 2020, 9:9, 2100, doi:10.3390/cells9092100.mdpi.com, doi.org.

15. Kory, P., The Global War on Ivermectin, International Covid Summit III, European Parliament, Brussels, covid19criticalcare.com/wp-content/uploads/2023/05/GLOBAL-WAR-ON-IVERMECTIN-PARLIAMENT.pdf.covid19criticalcare.com.

16. Kory (B), P., The Criminal Censorship of Ivermectin's Efficacy By The High-Impact Medical Journals - Part 1, Pierre Kory’s Medical Musings, pierrekory.substack.com/p/the-criminal-censorship-of-ivermectins.substack.com.

17. Kory (C) et al., Review of the Emerging Evidence Demonstrating the Efficacy of Ivermectin in the Prophylaxis and Treatment of COVID-19, American Journal of Therapeutics, doi:10.1097/MJT.0000000000001377.lww.com, doi.org.

18. Kory (D) et al., Review of the Emerging Evidence Demonstrating the Efficacy of Ivermectin in the Prophylaxis and Treatment of COVID-19, Frontiers in Pharmacology, doi:10.3389/fphar.2021.643369.archive.org, doi.org.

19. Kow et al., Pitfalls in Reporting Sample Size Calculation Across Randomized Controlled Trials Involving Ivermectin for the treatment of COVID-19, American Journal of Therapeutics, doi:10.1097/MJT.0000000000001441.lww.com, doi.org.

20. Lind et al., Increase in Outpatient Ivermectin Dispensing in the US During the COVID-19 Pandemic: A Cross-Sectional Analysis, Journal of General Internal Medicine, doi:10.1007/s11606-021-06948-6.springer.com, doi.org.

21. Liu et al., Crosstalk between neutrophil extracellular traps and immune regulation: insights into pathobiology and therapeutic implications of transfusion-related acute lung injury, Frontiers in Immunology, doi:10.3389/fimmu.2023.1324021.frontiersin.org, doi.org.

22. Loo et al., Recent Advances in Inhaled Nanoformulations of Vaccines and Therapeutics Targeting Respiratory Viral Infections, Pharmaceutical Research, doi:10.1007/s11095-023-03520-1.springer.com, doi.org.

23. Low et al., Repositioning Ivermectin for Covid-19 treatment: Molecular mechanisms of action against SARS-CoV-2 replication, Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease, doi:10.1016/j.bbadis.2021.166294.sciencedirect.com, doi.org.

24. Santin et al., Ivermectin: a multifaceted drug of Nobel prize-honored distinction with indicated efficacy against a new global scourge, COVID-19, New Microbes and New Infections, doi:10.1016/j.nmni.2021.100924.sciencedirect.com, doi.org.

25. Scheim et al., Sialylated Glycan Bindings from SARS-CoV-2 Spike Protein to Blood and Endothelial Cells Govern the Severe Morbidities of COVID-19, International Journal of Molecular Sciences, doi:10.3390/ijms242317039.mdpi.com, doi.org.

26. Schwartz, E., Does ivermectin have a place in the treatment of mild Covid-19?, New Microbes and New Infections, doi:10.1016/j.nmni.2022.100989.sciencedirect.com, doi.org.

27. Semiz, S., SIT1 transporter as a potential novel target in treatment of COVID-19, Biomolecular Concepts, doi:10.1515/bmc-2021-0017.degruyter.com, doi.org.

28. Turkia, M., A Continuation of a Timeline of Ivermectin-Related Events in the COVID-19 Pandemic [June 30, 2021], ResearchGate, doi:10.13140/RG.2.2.16973.36326.researchgate.net, doi.org.

29. Turkia (B), M., A timeline of ivermectin-related events in the COVID-19 pandemic, Research Gate, www.researchgate.net/publication/350610718_A_Timeline_of_Ivermectin-Related_Events_in_the_COVID-19_Pandemic_April_3_2021.researchgate.net.

30. Turkia (C), M., FLCCC Alliance MATH+ ascorbic acid and I-MASK+ ivermectin protocols for COVID-19 — a brief review, ResearchGate, www.researchgate.net/profile/Mika_Turkia/publication/345694745_FLCCC_Alliance_MATH_ascorbic_acid_and_I-MASK_ivermectin_protocols_for_COVID-19_-_A_Brief_Review/links/5fab010f4585150781078260/FLCCC-Alliance-MATH-ascorbic-acid-and-I-MASK-ivermectin-protocols-for-COVID-19-A-Brief-Review.pdf.researchgate.net.

31. Vora et al., White paper on Ivermectin as a potential therapy for COVID-19, Indian Journal of Tuberculosis, doi:10.1016/j.ijtb.2020.07.031.sciencedirect.com, doi.org.

32. Wang et al., Minimum manufacturing costs, national prices and estimated global availability of new repurposed therapies for COVID-19, medRxiv, doi:10.1101/2021.06.01.21258147.medrxiv.org, doi.org.

33. Wehbe et al., Repurposing Ivermectin for COVID-19: Molecular Aspects and Therapeutic Possibilities, Front. Immunol., doi:10.3389/fimmu.2021.663586.frontiersin.org, doi.org.

34. Yagisawa et al., Global trends in clinical trials of ivermectin for COVID-19—Part 2, The Japanese Journal of Antibiotics, doi:10.11553/antibiotics.77.1_45.doi.org, doi.org.

35. Yagisawa (B) et al., Global trends in clinical studies of ivermectin in COVID-19, The Japanese Journal of Antibiotics, 74-1, Mar 2021, jja-contents.wdc-jp.com/pdf/JJA74/74-1-open/74-1_44-95.pdf.wdc-jp.com.

36. Yemeke et al., Impact of the COVID-19 pandemic on the quality of medical products in Zimbabwe: a qualitative study based on key informant interviews with health system stakeholders, BMJ Open, doi:10.1136/bmjopen-2022-068923.bmj.com, doi.org.

37. Zaidi et al., The mechanisms of action of ivermectin against SARS-CoV-2—an extensive review, The Journal of Antibiotics, doi:10.1038/s41429-021-00491-6.nature.com, doi.org.

Formiga et al., 10 Jan 2021, peer-reviewed, 6 authors.

This Paper Ivermectin All

Ivermectin: an award-winning drug with expected antiviral activity against COVID-19

Fabio Rocha Formiga, Roger Leblanc, Juliana De Souza Rebouças, Leonardo Paiva Farias, Ronaldo Nascimento De Oliveira, Lindomar Pena

Journal of Controlled Release, doi:10.1016/j.jconrel.2020.10.009

Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre -including this research content -immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.

Declaration of Competing Interest The authors deny the existence of any conflicts of interest.

References

Ali, Afzal, Verma, Bhattacharya, Ahmad et al., Therapeutic efficacy of poly (lactic-co-glycolic acid) nanoparticles encapsulated ivermectin (nano-ivermectin) against brugian filariasis in experimental rodent model, Parasitol. Res, doi:10.1007/s00436-013-3696-5

Ali, Afzal, Verma, Misra-Bhattacharya, Ahmad et al., Improved antifilarial activity of ivermectin in chitosan-alginate nanoparticles against human lymphatic filarial parasite, Brugia malayi, Parasitol. Res, doi:10.1007/s00436-013-3466-4

Barrows, Campos, Powell, Prasanth, Schott-Lerner et al., A screen of FDA-approved drugs for inhibitors of Zika virus infection, Cell Host Microbe, doi:10.1016/j.chom.2016.07.004

Callaway, Cyranoski, Anti-parasite drugs sweep Nobel prize in medicine 2015, Nature, doi:10.1038/nature.2015.18507

Caly, Druce, Catton, Jans, Wagstaff, The FDA-approved drug Ivermectin inhibits the replication of SARS-CoV-2 in vitro, Antivir. Res, doi:10.1016/j.antiviral.2020.104787

Camargo, Sapin, Daloz, Maincent, Ivermectin-loaded microparticles for parenteral sustained release: in vitro characterization and effect of some formulation variables, J. Microencapsul, doi:10.3109/02652048.2010.501397

Chaccour, Ruiz-Castillo, Richardson, Moncunill, Casellas et al., The SARS-CoV-2 Ivermectin Navarra-ISGlobal trial (SAINT) to evaluate the potential of ivermectin to reduce COVID-19 transmission in low risk, non-severe COVID-19 patients in the first 48 hours after symptoms onset: a structured summary of a study protocol for a randomized control pilot trial, Trials, doi:10.1186/s13063-020-04421-z

Chan, Nano research for COVID-19, ACS Nano, doi:10.1021/acsnano.0c02540

Cojocaru, Botezat, Gardikiotis, Uritu, Dodi et al., Nanomaterials designed for antiviral drug delivery transport across biological barriers, Pharmaceutics, doi:10.3390/pharmaceutics12020171

Croci, Bottaro, Chan, Watanabe, Pezzullo et al., Liposomal systems as nanocarriers for the antiviral agent Ivermectin, Int. J. Biomater, doi:10.1155/2016/8043983

Ebbelaar, Venema, Van Dijk, Topical ivermectin in the treatment of Papulopustular rosacea: a systematic review of evidence and clinical guideline recommendations, Dermatol. Ther. (Heidelb), doi:10.1007/s13555-018-0249-y

Ghadiri, Young, Traini, Strategies to enhance drug absorption via nasal and pulmonary routes, Pharmaceutics, doi:10.3390/pharmaceutics11030113

Ho, Nichols, Edgar, Murgia, Loretz et al., Challenges and strategies in drug delivery systems for treatment of pulmonary infections, Eur. J. Pharm. Biopharm, doi:10.1016/j.ejpb.2019.09.002

Ketkar, Yang, Wormser, Wang, Lack of efficacy of ivermectin for prevention of a lethal Zika virus infection in a murine system, Diagn. Microbiol. Infect. Dis, doi:10.1016/j.diagmicrobio.2019.03.012

Liu, Guan, Qin, Zhang, Mao, Physicochemical properties affecting the fate of nanoparticles in pulmonary drug delivery, Drug Discov. Today, doi:10.1016/j.drudis.2019.09.023

Lv, Liu, Wang, Dang, Qiu et al., Ivermectin inhibits DNA polymerase UL42 of pseudorabies virus entrance into the nucleus and proliferation of the virus in vitro and vivo, Antivir. Res, doi:10.1016/j.antiviral.2018.09.010

Newman, Drug delivery to the lungs: challenges and opportunities, Ther. Deliv, doi:10.4155/tde-2017-0037

Ono, Tatsuo, Hidaka, Aoki, Minagawa et al., Measles viruses on throat swabs from measles patients use signaling lymphocytic activation molecule (CDw150) but not CD46 as a cellular receptor, J. Virol, doi:10.1128/JVI.75.9.4399-4401.2001

Onoue, Yamada, Chan, Nanodrugs: pharmacokinetics and safety, Int. J. Nanomedicine, doi:10.2147/IJN.S38378

Paranjpe, Müller-Goymann, Nanoparticle-mediated pulmonary drug delivery: a review, Int. J. Mol. Sci, doi:10.3390/ijms15045852

Pedersen, Ho, SARS-CoV-2: a storm is raging, J. Clin. Invest, doi:10.1172/JCI137647

Rizzo, Ivermectin, antiviral properties and COVID-19: a possible new mechanism of action, Naunyn Schmiedeberg's, Arch. Pharmacol, doi:10.1007/s00210-020-01902-5

Sandler, Firpo, Omoba, Vu, Menachery et al., Novel ionophores active against La Crosse virus identified through rapid antiviral screening, Antimicrob. Agents Chemother, doi:10.1128/AAC.00086-20

Schmith, Zhou, Lohmer, The approved dose of ivermectin alone is not the Ideal dose for the treatment of COVID-19, Clin. Pharmacol. Ther, doi:10.1002/cpt.1889

Surnar, Kamran, Shah, Basu, Kolishetti et al., Orally administrable therapeutic synthetic nanoparticle for Zika virus, ACS Nano, doi:10.1021/acsnano.9b02807

Takano, Sugano, Higashida, Hayashi, Machida et al., Oral absorption of poorly water-soluble drugs: computer simulation of fraction absorbed in humans from a miniscale dissolution test, Pharm. Res, doi:10.1007/s11095-006-0162-4

Ullio-Gamboa, Palma, Benoit, Allemandi, Picollo et al., Ivermectin lipid-based nanocarriers as novel formulations against head lice, Parasitol. Res, doi:10.1007/s00436-017-5510-2

Varghese, Kaukinen, Glasker, Bespalov, Hanski et al., Discovery of berberine, abamectin and ivermectin as antivirals against chikungunya and other alphaviruses, Antivir. Res, doi:10.1016/j.antiviral.2015.12.012

Wang, Lv, Ji, Wang, Qiu et al., Ivermectin treatment inhibits the replication of porcine circovirus 2 (PCV2) in vitro and mitigates the impact of viral infection in piglets, Virus Res, doi:10.1016/j.virusres.2019.01.010

Wölfel, Corman, Guggemos, Virological assessment of hospitalized patients with COVID-2019, Nature, doi:10.1038/s41586-020-2196-x

Xu, Han, Liu, Pang, Zheng et al., Antivirus effectiveness of ivermectin on dengue virus type 2 in Aedes albopictus, PLoS Negl. Trop. Dis, doi:10.1371/journal.pntd.0006934

Yan, Ci, Chen, Chen, Li et al., Anti-inflammatory effects of ivermectin in mouse model of allergic asthma, Inflamm. Res, doi:10.1007/s00011-011-0307-8

Yang, Atkinson, Wang, Lee, Bogoyevitch et al., The broad spectrum antiviral ivermectin targets the host nuclear transport importin alpha/beta1 heterodimer, Antivir. Res, doi:10.1016/j.antiviral.2020.104760

Zhang, Song, Ci, An, Ju et al., Ivermectin inhibits LPS-induced production of inflammatory cytokines and improves LPS-induced survival in mice, Inflamm. Res, doi:10.1007/s00011-008-8007-8

Zhang, Zhou, Wei, Yue, Wang et al., Histopathologic changes and SARS-CoV-2 imunostaining in the lung of a patient with COVID-19, Ann. Intern. Med, doi:10.7326/M20-0533

Zheng, Fan, Yu, Feng, Lou et al., Viral load dynamics and disease severity in patients infected with SARS-CoV-2 in Zhejiang Province, China, BMJ, doi:10.1136/bmj.m1443

Zhou, Leung, Tang, Parumasivam, Loh et al., Inhaled formulations and pulmonary drug delivery systems for respiratory infections, Adv. Drug Deliv. Rev, doi:10.1016/j.addr.2014.10.022

Zhou, Yang, Wang, A pneumonia outbreak associated with a new coronavirus of probable bat origin, Nature, doi:10.1038/s41586-020-2012-7

Zou, Ruan, Huang, Liang, Huang et al., SARS-CoV-2 viral load in upper respiratory specimens of infected patients, N. Engl. J. Med, doi:10.1056/NEJMc2001737

Download Image

Please send us corrections, updates, or comments. c19early involves the extraction of 100,000+ datapoints from thousands of papers. Community updates help ensure high accuracy. Treatments and other interventions are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.

Submit

Post

@CovidAnalysis

FAQ

Public domain CC0 1.0